| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/01/2004 | WO2004054989A1 Novel 2,4-diamino-1,3,5-triazine derivative |
| 07/01/2004 | WO2004054985A1 3h-quinazolin-4-one derivatives |
| 07/01/2004 | WO2004054979A1 Jnk inhibitors |
| 07/01/2004 | WO2004054973A2 Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor |
| 07/01/2004 | WO2004054968A2 25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol) |
| 07/01/2004 | WO2004054963A1 Sphingolipid derivatives modified by polyethylene glycol and composition containing the same |
| 07/01/2004 | WO2004054957A2 Valproic acid analogues and pharmaceutical compositions thereof |
| 07/01/2004 | WO2004054904A1 Extendable belt conveyor |
| 07/01/2004 | WO2004054657A1 Combined antisense oligonucleotide cancer therapy |
| 07/01/2004 | WO2004054638A2 Dermal, transdermal, mucosal or transmucosal ingredient delivery devices |
| 07/01/2004 | WO2004054630A1 Quaternary ammonium esters for disinfection and preservation |
| 07/01/2004 | WO2004054621A1 Water-soluble clathrates of ziprasidone and its salts, and the preparation methods therefor |
| 07/01/2004 | WO2004054619A1 Light-blocking agent and film-forming composition |
| 07/01/2004 | WO2004054617A1 Preventives and/or remedies for central diseases |
| 07/01/2004 | WO2004054616A1 Antagonist and agonist binding to strong binding site of chemokine receptor |
| 07/01/2004 | WO2004054601A2 Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis |
| 07/01/2004 | WO2004054600A1 Pharmaceutical compound containing silymarin and carbopol®, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus |
| 07/01/2004 | WO2004054596A1 A medicament containing epidemium extract for treatment of prostatic hyperplasia and prostatitis |
| 07/01/2004 | WO2004054595A1 A method for preparing low polar ginsenoside and aglucon thereof by catalytic pyrolysis |
| 07/01/2004 | WO2004054594A1 Cell death inhibitor |
| 07/01/2004 | WO2004054591A1 The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion |
| 07/01/2004 | WO2004054590A1 New ginsenoside used in antitumor agents |
| 07/01/2004 | WO2004054589A1 Intravitreally-injectable solution for the treatment of vitreous haemorrhages |
| 07/01/2004 | WO2004054588A1 Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate |
| 07/01/2004 | WO2004054587A1 Treatment of neuro-psychiatric disorders |
| 07/01/2004 | WO2004054586A1 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors |
| 07/01/2004 | WO2004054583A1 Crystalline forms of gatifloxacin and processes for preparation |
| 07/01/2004 | WO2004054582A1 Combination therapy for the treatment of pain |
| 07/01/2004 | WO2004054580A1 Tiotropium containing hfc solution formulations |
| 07/01/2004 | WO2004054578A1 Treatment of psychostimulant addiction |
| 07/01/2004 | WO2004054577A1 Alpha-2-delta ligands to treat ocd and related diseases |
| 07/01/2004 | WO2004054576A1 Pharmaceutical compositions of sertaconazole for vaginal use |
| 07/01/2004 | WO2004054575A1 Combinations of valsartan with cox-2 inhibitors |
| 07/01/2004 | WO2004054574A1 Solid drug for oral use |
| 07/01/2004 | WO2004054573A1 Method and composition for inhibiting carbohydrate digestion |
| 07/01/2004 | WO2004054572A2 Novel benzopyran analogs and their use for the treatment of glaucoma |
| 07/01/2004 | WO2004054571A1 Controlled release preparations comprising tramadol and topiramate |
| 07/01/2004 | WO2004054570A1 Combinations of medicaments comprising an alcohol deterrent for treating alcohol dependence or alcohol abuse |
| 07/01/2004 | WO2004054569A1 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
| 07/01/2004 | WO2004054568A1 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| 07/01/2004 | WO2004054567A1 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause |
| 07/01/2004 | WO2004054566A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| 07/01/2004 | WO2004054565A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 07/01/2004 | WO2004054564A1 Gabapentin analogues for fibromyalgia and other related disorders |
| 07/01/2004 | WO2004054563A1 Alpha-2-delta ligand for the treatment of sexual dysfunction |
| 07/01/2004 | WO2004054562A1 Method for preventing abuse of methylphenidate |
| 07/01/2004 | WO2004054561A1 Inhibiting the adhesion of keratinophilic fungi |
| 07/01/2004 | WO2004054560A1 Alpha-2-delta ligand to treat lower urinary tract symptoms |
| 07/01/2004 | WO2004054559A1 Alpha2delta ligands for different pharmaceutical uses |
| 07/01/2004 | WO2004054558A2 Reduction of breast density with 4-hydroxy tamoxifen |
| 07/01/2004 | WO2004054557A2 Treatment of mastalgia with 4-hydroxy tamoxifen |
| 07/01/2004 | WO2004054556A1 Pharmaceutical porous particles |
| 07/01/2004 | WO2004054554A1 Transdermal buprenorphine to treat pain in sickle cell crisis |
| 07/01/2004 | WO2004054553A1 Transdermal buprenorphine dosage regimen for analgesia |
| 07/01/2004 | WO2004054552A1 Transdermal composition of an antivomiting agent |
| 07/01/2004 | WO2004054551A1 Film-type preparations for transmucosal administration of nicotine and method for the production thereof |
| 07/01/2004 | WO2004054550A1 An extended release pharmaceutical composition of phenytoin sodium |
| 07/01/2004 | WO2004054549A1 A topical nanoparticulate spironolactone formulation |
| 07/01/2004 | WO2004054548A1 Method and reagents for treating or preventing atherosclerosis and diseases associated therewith |
| 07/01/2004 | WO2004054547A1 Stable topiramate formulations |
| 07/01/2004 | WO2004054546A1 Formulation for fast dissolution of lipophilic compounds |
| 07/01/2004 | WO2004054544A1 Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof |
| 07/01/2004 | WO2004054543A1 Process for the chemical stabilization of a solubilized retinoid in a solvent using a base |
| 07/01/2004 | WO2004054542A2 Oral drug delivery system comprising high viscosity liquid carrier materials |
| 07/01/2004 | WO2004054538A1 Mastitis treatment |
| 07/01/2004 | WO2004054532A1 Method for protecting the skin from aging |
| 07/01/2004 | WO2004054515A2 Thrombopoietin mimetics |
| 07/01/2004 | WO2004054514A2 C-6 modified indazolylpyrrolotriazines |
| 07/01/2004 | WO2004054513A2 Methods and compositions for treating and preventing ear infections |
| 07/01/2004 | WO2004054511A2 Analgesic combination comprising nalbuphine |
| 07/01/2004 | WO2004054509A2 Tetracyclines as anti-fungal agents for treatment of ringworm |
| 07/01/2004 | WO2004054507A2 Indolizine compounds |
| 07/01/2004 | WO2004054505A2 Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors |
| 07/01/2004 | WO2004054501A2 Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| 07/01/2004 | WO2004054500A2 Preparation of submicron sized particles with polymorph control and new polymorph of itraconazole |
| 07/01/2004 | WO2004054497A2 Use of a trpm8-activating substance for the treatment of tumours |
| 07/01/2004 | WO2004047673A3 Treatment of liver disease with active vitamin d compounds |
| 07/01/2004 | WO2004041174A3 Compositions for darkening the skin and/or hair |
| 07/01/2004 | WO2004039774A3 Mitotic kinesin inhibitors |
| 07/01/2004 | WO2004037197A3 Antifungal formulations |
| 07/01/2004 | WO2004032929A3 Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer’s disease |
| 07/01/2004 | WO2004032909A3 Stabilized pharmaceutical composition containing basic excipients |
| 07/01/2004 | WO2004030627A3 Synergistic methods and compositions for treating cancer |
| 07/01/2004 | WO2004029025A3 Methods and compositions for the treatment of autoimmune disorders using clofarabine |
| 07/01/2004 | WO2004028541A3 Composition for the treatment of nasopharyngeal carcinoma and use thereof |
| 07/01/2004 | WO2004028480A3 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| 07/01/2004 | WO2004028474A3 Caspase inhibitors as anticancer agents |
| 07/01/2004 | WO2004028446A3 Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease |
| 07/01/2004 | WO2004026306A3 Pyrazole derivatives as transforming growth factor (tgf) inhibitors |
| 07/01/2004 | WO2004026256A3 Sustained-release opioid formulations and methods of use |
| 07/01/2004 | WO2004026246A3 Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
| 07/01/2004 | WO2004026239A3 Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption |
| 07/01/2004 | WO2004026237A3 Compounds for the treatment of premature ejaculation |
| 07/01/2004 | WO2004026116A3 Use of etodoclac to treat hyperplasia |
| 07/01/2004 | WO2004024683A3 COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR |
| 07/01/2004 | WO2004024083A3 Methods of bone healing |
| 07/01/2004 | WO2004023984A3 Novel composition and method for treatment of upper respiratory conditions |
| 07/01/2004 | WO2004020014A3 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 07/01/2004 | WO2004019892A3 Drug delivery system for treating urinary incontinence |
| 07/01/2004 | WO2004019884A3 Agents and methods for enhancing bone formation |